These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 35409316)
1. The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease. Giat E; Ben-Zvi I; Lidar M; Livneh A Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409316 [TBL] [Abstract][Full Text] [Related]
3. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360 [TBL] [Abstract][Full Text] [Related]
5. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Stankovic Stojanovic K; Delmas Y; Torres PU; Peltier J; Pelle G; Jéru I; Colombat M; Grateau G Nephrol Dial Transplant; 2012 May; 27(5):1898-901. PubMed ID: 21931121 [TBL] [Abstract][Full Text] [Related]
6. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327 [TBL] [Abstract][Full Text] [Related]
7. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience. Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310 [TBL] [Abstract][Full Text] [Related]
8. The clinical role of anakinra in the armamentarium against familial Mediterranean fever. Parlar K; Ates MB; Egeli BH; Ugurlu S Expert Rev Clin Immunol; 2024 May; 20(5):441-453. PubMed ID: 38133629 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Moser C; Pohl G; Haslinger I; Knapp S; Rowczenio D; Russel T; Lachmann HJ; Lang U; Kovarik J Nephrol Dial Transplant; 2009 Feb; 24(2):676-8. PubMed ID: 19033248 [TBL] [Abstract][Full Text] [Related]
10. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder. Portincasa P; Scaccianoce G; Palasciano G Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever. Erkilet HK; Gezgin Yildirim D; Esmeray P; Söylemezoğlu O Pediatr Int; 2023; 65(1):e15588. PubMed ID: 37658625 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914 [TBL] [Abstract][Full Text] [Related]
13. IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations. Kharouf F; Tsemach-Toren T; Ben-Chetrit E Clin Exp Rheumatol; 2022 Sep; 40(8):1567-1574. PubMed ID: 36062765 [TBL] [Abstract][Full Text] [Related]
14. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review. Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S Front Immunol; 2020; 11():971. PubMed ID: 32670263 [No Abstract] [Full Text] [Related]
15. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Eroglu FK; Beşbaş N; Topaloglu R; Ozen S Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Calligaris L; Marchetti F; Tommasini A; Ventura A Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171 [TBL] [Abstract][Full Text] [Related]
17. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Gül A Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study. Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391 [TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis. Sargin G; Kose R; Senturk T Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269 [TBL] [Abstract][Full Text] [Related]
20. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Goto T; Miyazaki Y; Nakayamada S; Shiraishi N; Yoshinaga T; Tanaka Y; Nakamura T Mod Rheumatol Case Rep; 2023 Jan; 7(1):237-242. PubMed ID: 35349715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]